Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1996 4
1997 9
1998 11
1999 12
2000 24
2001 46
2002 55
2003 83
2004 94
2005 116
2006 105
2007 121
2008 136
2009 131
2010 143
2011 171
2012 139
2013 131
2014 123
2015 133
2016 112
2017 97
2018 88
2019 77
2020 67
2021 62
2022 53
2023 45
2024 57
2025 58
2026 32

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,220 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators. LaRosa JC, et al. N Engl J Med. 2005 Apr 7;352(14):1425-35. doi: 10.1056/NEJMoa050461. Epub 2005 Mar 8. N Engl J Med. 2005. PMID: 15755765 Free article. Clinical Trial.
RESULTS: The mean LDL cholesterol levels were 77 mg per deciliter (2.0 mmol per liter) during treatment with 80 mg of atorvastatin and 101 mg per deciliter (2.6 mmol per liter) during treatment with 10 mg of atorvastatin. ...CONCLUSIONS: Intensive lipid-lowering the …
RESULTS: The mean LDL cholesterol levels were 77 mg per deciliter (2.0 mmol per liter) during treatment with 80 mg of atorvastatin an …
Safety and Efficacy of Atorvastatin for Chronic Subdural Hematoma in Chinese Patients: A Randomized ClinicalTrial.
Jiang R, Zhao S, Wang R, Feng H, Zhang J, Li X, Mao Y, Yuan X, Fei Z, Zhao Y, Yu X, Poon WS, Zhu X, Liu N, Kang D, Sun T, Jiao B, Liu X, Yu R, Zhang J, Gao G, Hao J, Su N, Yin G, Zhu X, Lu Y, Wei J, Hu J, Hu R, Li J, Wang D, Wei H, Tian Y, Lei P, Dong JF, Zhang J. Jiang R, et al. JAMA Neurol. 2018 Nov 1;75(11):1338-1346. doi: 10.1001/jamaneurol.2018.2030. JAMA Neurol. 2018. PMID: 30073290 Free PMC article. Clinical Trial.
Nonsurgical treatments remain limited and ineffective. Our recent studies suggest that atorvastatin reduces hematomas and improves the clinical outcomes of patients with CSDH. OBJECTIVE: To investigate the safety and therapeutic efficacy of atorvastatin to nonsurgic …
Nonsurgical treatments remain limited and ineffective. Our recent studies suggest that atorvastatin reduces hematomas and improves th …
Atorvastatin before percutaneous coronary intervention: A systematic review and meta-analysis.
García-Campa M, Flores-Ramírez R, Rojo-Garza S, Carrizales-Sepúlveda EF, Regalado-Ceballos D, Reyes-Araiza R, Álvarez-Villalobos N, Rodríguez-Gutiérrez R, Azpiri-López JR. García-Campa M, et al. PLoS One. 2024 Jan 2;19(1):e0293404. doi: 10.1371/journal.pone.0293404. eCollection 2024. PLoS One. 2024. PMID: 38165842 Free PMC article.
Patients presenting with STEMI or NSTEMI benefit from high-dose atorvastatin pre-loading before PCI by reducing MACE at 30 days. The use of high-dose atorvastatin in STEMI patients reduced all-cause mortality. The beneficial effects of atorvastatin pre-loadin …
Patients presenting with STEMI or NSTEMI benefit from high-dose atorvastatin pre-loading before PCI by reducing MACE at 30 days. The …
Efficacy and Safety of Metformin and Atorvastatin Combination Therapy vs. Monotherapy with Either Drug in Type 2 Diabetes Mellitus and Dyslipidemia Patients (ATOMIC): Double-Blinded Randomized Controlled Trial.
Lee JE, Yu SH, Kim SR, Ahn KJ, Song KH, Lee IK, Shon HS, Kim IJ, Lim S, Kim DM, Chung CH, Lee WY, Lee SH, Kim DJ, Cho SR, Jung CH, Jeon HJ, Lee SH, Park KY, Rhee SY, Kim SG, Park SO, Kim DJ, Kim BJ, Lee SA, Kim YH, Kim KS, Seo JA, Nam-Goong IS, Lee CW, Kim DK, Kim SW, Cho CG, Kim JH, Kim YJ, Yoo JM, Min KW, Lee MK. Lee JE, et al. Diabetes Metab J. 2024 Jul;48(4):730-739. doi: 10.4093/dmj.2023.0077. Epub 2024 May 20. Diabetes Metab J. 2024. PMID: 38763510 Free PMC article. Clinical Trial.
One hundred eighty-five eligible subjects were randomized to the combination group (metformin+atorvastatin), metformin group (metformin+atorvastatin placebo), and atorvastatin group (atorvastatin+metformin placebo). ...The combination group also showed …
One hundred eighty-five eligible subjects were randomized to the combination group (metformin+atorvastatin), metformin group (metform …
Effect of atorvastatin on testosterone levels.
Shawish MI, Bagheri B, Musini VM, Adams SP, Wright JM. Shawish MI, et al. Cochrane Database Syst Rev. 2021 Jan 22;1(1):CD013211. doi: 10.1002/14651858.CD013211.pub2. Cochrane Database Syst Rev. 2021. PMID: 33482034 Free PMC article.
A potential reduction in androgen levels, caused by atorvastatin might cause negative effects in most settings. In contrast, in the setting of polycystic ovary syndrome (PCOS), reducing excessive levels of androgens with atorvastatin could be beneficial. ...AUTHORS' …
A potential reduction in androgen levels, caused by atorvastatin might cause negative effects in most settings. In contrast, in the s …
Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.
Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, Sun S, LeBeaut AP, Sager PT, Veltri EP; Ezetimibe Study Group. Ballantyne CM, et al. Circulation. 2003 May 20;107(19):2409-15. doi: 10.1161/01.CIR.0000068312.21969.C8. Epub 2003 Apr 28. Circulation. 2003. PMID: 12719279 Clinical Trial.
The primary efficacy end point was percentage reduction in LDL-C for pooled ezetimibe plus atorvastatin versus pooled atorvastatin treatment groups. Ezetimibe plus atorvastatin significantly improved LDL-C, HDL cholesterol (HDL-C), triglycerides, total choles …
The primary efficacy end point was percentage reduction in LDL-C for pooled ezetimibe plus atorvastatin versus pooled atorvastatin …
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Schwartz GG, et al. JAMA. 2001 Apr 4;285(13):1711-8. doi: 10.1001/jama.285.13.1711. JAMA. 2001. PMID: 11277825 Clinical Trial.
Likewise, there were no significant differences between the atorvastatin group and the placebo group in the incidence of secondary outcomes of coronary revascularization procedures, worsening heart failure, or worsening angina, although there were fewer strokes in the a …
Likewise, there were no significant differences between the atorvastatin group and the placebo group in the incidence of secondary ou …
Effect of rosuvastatin versus atorvastatin on new-onset diabetes mellitus in patients treated with high-intensity statin therapy for coronary artery disease: a post-hoc analysis from the LODESTAR randomized clinical trial.
Hong SJ, Lee YJ, Kang WC, Hong BK, Lee JY, Lee JB, Yang TH, Yoon J, Lee SJ, Ahn CM, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Hong MK; LODESTAR investigators. Hong SJ, et al. Cardiovasc Diabetol. 2024 Aug 7;23(1):287. doi: 10.1186/s12933-024-02386-w. Cardiovasc Diabetol. 2024. PMID: 39113067 Free PMC article. Clinical Trial.
BACKGROUND: The impact of rosuvastatin versus atorvastatin on new-onset diabetes mellitus (NODM) among patients treated with high-intensity statin therapy for coronary artery disease (CAD) remains to be clarified. This study aimed to evaluate the risk of NODM in patients w …
BACKGROUND: The impact of rosuvastatin versus atorvastatin on new-onset diabetes mellitus (NODM) among patients treated with high-int …
Impact of atorvastatin on erectile dysfunction: A meta-analysis and systematic review.
Su H, Lu Y, Ma C, Li H, Su X. Su H, et al. Andrologia. 2022 Jul;54(6):e14408. doi: 10.1111/and.14408. Epub 2022 Feb 27. Andrologia. 2022. PMID: 35224753
Atorvastatin may be an effective treatment for erectile dysfunction (ED). The purpose of this meta-analysis was to determine whether atorvastatin therapy is effective in the treatment of ED. ...A meta-analysis of randomized controlled trials (RCTs) was done to inves …
Atorvastatin may be an effective treatment for erectile dysfunction (ED). The purpose of this meta-analysis was to determine whether …
[Efficacy and safety of atorvastatin in major cardiovascular events: Meta-analysis].
Villegas-Quintero VE, Rivas-Ruíz R, García-Rivero AA, Rivera-Lara P, González-Tovar NB. Villegas-Quintero VE, et al. Rev Med Inst Mex Seguro Soc. 2023 Oct 2;61(Suppl 3):S407-S415. doi: 10.5281/zenodo.8319748. Rev Med Inst Mex Seguro Soc. 2023. PMID: 37934798 Free PMC article. Spanish.
INTRODUCTION: Atorvastatin has been used in the management of dyslipidemia and little is known about the efficacy and safety of high-dose atorvastatin administration for secondary prevention of Major Cardiovascular Events (MACE). ...In the analysis of adverse effect …
INTRODUCTION: Atorvastatin has been used in the management of dyslipidemia and little is known about the efficacy and safety of high- …
2,220 results